La lecture à portée de main
Découvre YouScribe en t'inscrivant gratuitement
Je m'inscrisDécouvre YouScribe en t'inscrivant gratuitement
Je m'inscrisDescription
Informations
Publié par | frost-sullivan |
Publié le | 20 janvier 2014 |
Nombre de lectures | 3 |
Langue | English |
Extrait
PR Newswire
MOUNTAIN VIEW, California, Jan. 20, 2014
-- BeneChill's RhinoChill helps achieve effective, time critical, and safe brain cooling in both pre-clinical as well as clinical settings
Based on its recent analysis of the therapeutic hypothermia market for cardiology, Frost & Sullivan recognizes BeneChill, Inc. with the 2014 Frost & Sullivan Award for Technology Innovation Leadership. BeneChill's RhinoChill intranasal cooling system is a nasopharyngeal device that can induce therapeutic hypothermia during active resuscitation after a cardiac arrest and continue maintaining the temperature while the patient is in an ambulance. The system is unique—it is noninvasive, time critical, and can be used by nonmedical personnel in the field to prevent brain damage associated with cardiac arrest.